Tonsil surgery is reduced with Bactek-MV130

Amigadalitis InmunologíaApril 2019

Human Vaccines & Immunotherapeutics publishes a study showing that Bactek-MV130, in combination with antibiotics, reduces the need of tonsillectomy in adult patients with recurrent tonsillitis. The study conducted in two hospitals in Asturias - Spain by doctors Luis-Amando García González and Federico Arrutia Díez compares patients treated only with antibiotics or with antibiotics plus Bactek-MV130.
More info


Premios Inmunotek LogoJanuary 2019

The INMUNOTEK Prizes were awarded at the event held during the 9th Scientific Conference of the SICAM (Community Immunology Society of Madrid) held in Madrid on 18th January. These awards are now in their fourth call and aim to recognize the best clinical and basic research presented during this Conference.
More info

TIbV - Trained Immunity-based Vaccines

January 2019

Frontiers in Immunology publishes the article entitled "Trained Immunity-Based Vaccines: A New Paradigm for the Development of Broad-Spectrum Anti-infectious Formulations" in the Topic Research issue of Reverse Vaccinology, within the section of Vaccines and Molecular Therapeutics. In this review, the potential of "Trained Immunity" in the development of new vaccines (TIbV) and their possible clinical applications are outlined. The article is co-authored by members of INMUNOTEK among leading experts in the field.
More info

Allergoids coupled to mannan. A review

vacunas alergiaDecember 2018

Novel glycoconjugates of allergoids coupled to mannan for a next generation of allergy vaccines. Allergo Journal International publishes a review about the development and main features of these novel vaccines targeting dendritic cells.
More info

iGEM 2018 competition

iGEM 2018November 2018

The iGEM-Madrid team, sponsored by INMUNOTEK, has been awarded in the international competition held in Boston (iGEM 2018). The project "IoBT-Internet of Bio-Things" is an automatic system where engineering, communications and biosensors of the latest generation based on aptamers are integrated to detect allergen contamination in the air of the cities. The iGEM competition (International Genetically Engineered Machine) aims to encourage students and recent graduates to design bioengineering prototypes that provide imaginative solutions to real needs and therefore with commercial interest.
More info

Novel allergoid-mannan vaccine in veterinary medicine

PerroOctober 2018

Veterinary Dermatology has published a clinical trial with dogs suffering atopic dermatitis with a novel allergoid-mannan glycoconjugate vaccine developed by INMUNOTEK.
More info

Mosquito allergy

July 2018

Allergy to mosquitoes and mites is common in certain geographic areas and both have important allergens such as tropomyosin that can lead to cross-reactions between them. A study has been published in Clinical Experimental Allergy which shows that the mosquito Aedes aegypti and the mite Dermatophagoides pteronyssinus share regions in their tropomyosin that justify the cross-response of antibodies and T cells.
More info

ICS 2018 Prize

Logo ICS 18July 2018

Prize received to the best communication (Biomedical Oligosaccharides section) during the 29th International Carbohydrate Symposium (ICS 2018 - Lisbon). The award-winning study was carried out in the Department of Chemical and Structural Biology of the Molecular Biology Center of Madrid with the collaboration of INMUNOTEK.
More info

EAACI 2018 Awards

Alergia e InmunologiaJune 2018

New awards for two studies presented at the Congress of the EAACI 2018 (European Academy of Allergy and Clinical Immunology) (Munich, Germany). Both studies, carried out in the Department of Biochemistry of the Complutense University of Madrid and which have had the participation of INMUNOTEK, have been awarded as the best communications in their respective sessions.
More info

Sublingual mannan-allergoid conjugates

vacunas alergiaFebruary 2018

A new study of allergoids conjugated with mannan has been published in Allergy. In this work, the oral mucosa is experimentally analyzed as a route for the administration of these glycoconjugates. Its lower allergenicity, greater uptake by dendritic cells and immunomodulatory properties makes them good candidates for the development of safer and more effective anti-allergic sublingual vaccines.
More info